@misc{drewry_a.m._antipyretic_2017,
	title = {Antipyretic {Therapy} in {Critically} {Ill} {Septic} {Patients}: {A} {Systematic} {Review} and {Meta}-{Analysis}},
	url = {http://journals.lww.com/ccmjournal/pages/default.aspx},
	abstract = {OBJECTIVE:: This meta-analysis aimed to examine the impact of antipyretic therapy on mortality in critically ill septic adults. DATA SOURCES:: Literature searches were implemented in Ovid Medline, Embase, Scopus, Cumulative Index of Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, NHS Economic Evaluation Database, and ClinicalTrials.gov through February 2016. STUDY SELECTION:: Inclusion criteria were observational or randomized studies of septic patients, evaluation of antipyretic treatment, mortality reported, and English-language version available. Studies were excluded if they enrolled pediatric patients, patients with neurologic injury, or healthy volunteers. Criteria were applied by two independent reviewers. DATA EXTRACTION:: Two reviewers independently extracted data and evaluated methodologic quality. Outcomes included mortality, frequency of shock reversal, acquisition of nosocomial infections, and changes in body temperature, heart rate, and minute ventilation. Randomized and observational studies were analyzed separately. DATA SYNTHESIS:: Eight randomized studies (1,507 patients) and eight observational studies (17,432 patients) were analyzed. Antipyretic therapy did not reduce 28-day/hospital mortality in the randomized studies (relative risk, 0.93; 95\% CI, 0.77-1.13; I = 0.0\%) or observational studies (odds ratio, 0.90; 95\% CI, 0.54-1.51; I = 76.1\%). Shock reversal (relative risk, 1.13; 95\% CI, 0.68-1.90; I = 51.6\%) and acquisition of nosocomial infections (relative risk, 1.13; 95\% CI, 0.61-2.09; I = 61.0\%) were also unchanged. Antipyretic therapy decreased body temperature (mean difference, -0.38degreeC; 95\% CI, -0.63 to -0.13; I = 84.0\%), but not heart rate or minute ventilation. CONCLUSIONS:: Antipyretic treatment does not significantly improve 28-day/hospital mortality in adult patients with sepsis.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. Copyright © by 2017 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.},
	journal = {Critical Care Medicine},
	author = {{Drewry A.M.} and {Ablordeppey E.A.} and {Murray E.T.} and {Stoll C.R.T.} and {Izadi S.R.} and {Dalton C.M.} and {Hardi A.C.} and {Fowler S.A.} and {Fuller B.M.} and {Colditz G.A.}},
	year = {2017},
	keywords = {*antipyretic agent, *critically ill patient, Child, Cochrane Library, Embase, English (language), Medline, Scopus, adult, body temperature, controlled clinical trial, controlled study, drug therapy, economic evaluation, heart rate, hospital infection, human, hypothermia, licence, lung minute volume, medical literature, meta analysis, mortality, nervous system, nursing, observational study, odds ratio, outpatient department, randomized controlled trial, risk factor, sepsis, systematic review, volunteer}
}

{"_id":"5uy8AYkbBgsxZKJFp","bibbaseid":"drewryam-ablordeppeyea-murrayet-stollcrt-izadisr-daltoncm-hardiac-fowlersa-etal-antipyretictherapyincriticallyillsepticpatientsasystematicreviewandmetaanalysis-2017","downloads":0,"creationDate":"2017-05-12T20:20:57.947Z","title":"Antipyretic Therapy in Critically Ill Septic Patients: A Systematic Review and Meta-Analysis","author_short":["Drewry A.M.","Ablordeppey E.A.","Murray E.T.","Stoll C.R.T.","Izadi S.R.","Dalton C.M.","Hardi A.C.","Fowler S.A.","Fuller B.M.","Colditz G.A."],"year":2017,"bibtype":"misc","biburl":"http://bibbase.org/zotero/gxu917","bibdata":{"bibtype":"misc","type":"misc","title":"Antipyretic Therapy in Critically Ill Septic Patients: A Systematic Review and Meta-Analysis","url":"http://journals.lww.com/ccmjournal/pages/default.aspx","abstract":"OBJECTIVE:: This meta-analysis aimed to examine the impact of antipyretic therapy on mortality in critically ill septic adults. DATA SOURCES:: Literature searches were implemented in Ovid Medline, Embase, Scopus, Cumulative Index of Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, NHS Economic Evaluation Database, and ClinicalTrials.gov through February 2016. STUDY SELECTION:: Inclusion criteria were observational or randomized studies of septic patients, evaluation of antipyretic treatment, mortality reported, and English-language version available. Studies were excluded if they enrolled pediatric patients, patients with neurologic injury, or healthy volunteers. Criteria were applied by two independent reviewers. DATA EXTRACTION:: Two reviewers independently extracted data and evaluated methodologic quality. Outcomes included mortality, frequency of shock reversal, acquisition of nosocomial infections, and changes in body temperature, heart rate, and minute ventilation. Randomized and observational studies were analyzed separately. DATA SYNTHESIS:: Eight randomized studies (1,507 patients) and eight observational studies (17,432 patients) were analyzed. Antipyretic therapy did not reduce 28-day/hospital mortality in the randomized studies (relative risk, 0.93; 95% CI, 0.77-1.13; I = 0.0%) or observational studies (odds ratio, 0.90; 95% CI, 0.54-1.51; I = 76.1%). Shock reversal (relative risk, 1.13; 95% CI, 0.68-1.90; I = 51.6%) and acquisition of nosocomial infections (relative risk, 1.13; 95% CI, 0.61-2.09; I = 61.0%) were also unchanged. Antipyretic therapy decreased body temperature (mean difference, -0.38degreeC; 95% CI, -0.63 to -0.13; I = 84.0%), but not heart rate or minute ventilation. CONCLUSIONS:: Antipyretic treatment does not significantly improve 28-day/hospital mortality in adult patients with sepsis.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. Copyright © by 2017 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.","journal":"Critical Care Medicine","author":[{"firstnames":[],"propositions":[],"lastnames":["Drewry A.M."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Ablordeppey E.A."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Murray E.T."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Stoll C.R.T."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Izadi S.R."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Dalton C.M."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Hardi A.C."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Fowler S.A."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Fuller B.M."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Colditz G.A."],"suffixes":[]}],"year":"2017","keywords":"*antipyretic agent, *critically ill patient, Child, Cochrane Library, Embase, English (language), Medline, Scopus, adult, body temperature, controlled clinical trial, controlled study, drug therapy, economic evaluation, heart rate, hospital infection, human, hypothermia, licence, lung minute volume, medical literature, meta analysis, mortality, nervous system, nursing, observational study, odds ratio, outpatient department, randomized controlled trial, risk factor, sepsis, systematic review, volunteer","bibtex":"@misc{drewry_a.m._antipyretic_2017,\n\ttitle = {Antipyretic {Therapy} in {Critically} {Ill} {Septic} {Patients}: {A} {Systematic} {Review} and {Meta}-{Analysis}},\n\turl = {http://journals.lww.com/ccmjournal/pages/default.aspx},\n\tabstract = {OBJECTIVE:: This meta-analysis aimed to examine the impact of antipyretic therapy on mortality in critically ill septic adults. DATA SOURCES:: Literature searches were implemented in Ovid Medline, Embase, Scopus, Cumulative Index of Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, NHS Economic Evaluation Database, and ClinicalTrials.gov through February 2016. STUDY SELECTION:: Inclusion criteria were observational or randomized studies of septic patients, evaluation of antipyretic treatment, mortality reported, and English-language version available. Studies were excluded if they enrolled pediatric patients, patients with neurologic injury, or healthy volunteers. Criteria were applied by two independent reviewers. DATA EXTRACTION:: Two reviewers independently extracted data and evaluated methodologic quality. Outcomes included mortality, frequency of shock reversal, acquisition of nosocomial infections, and changes in body temperature, heart rate, and minute ventilation. Randomized and observational studies were analyzed separately. DATA SYNTHESIS:: Eight randomized studies (1,507 patients) and eight observational studies (17,432 patients) were analyzed. Antipyretic therapy did not reduce 28-day/hospital mortality in the randomized studies (relative risk, 0.93; 95\\% CI, 0.77-1.13; I = 0.0\\%) or observational studies (odds ratio, 0.90; 95\\% CI, 0.54-1.51; I = 76.1\\%). Shock reversal (relative risk, 1.13; 95\\% CI, 0.68-1.90; I = 51.6\\%) and acquisition of nosocomial infections (relative risk, 1.13; 95\\% CI, 0.61-2.09; I = 61.0\\%) were also unchanged. Antipyretic therapy decreased body temperature (mean difference, -0.38degreeC; 95\\% CI, -0.63 to -0.13; I = 84.0\\%), but not heart rate or minute ventilation. CONCLUSIONS:: Antipyretic treatment does not significantly improve 28-day/hospital mortality in adult patients with sepsis.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. Copyright © by 2017 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.},\n\tjournal = {Critical Care Medicine},\n\tauthor = {{Drewry A.M.} and {Ablordeppey E.A.} and {Murray E.T.} and {Stoll C.R.T.} and {Izadi S.R.} and {Dalton C.M.} and {Hardi A.C.} and {Fowler S.A.} and {Fuller B.M.} and {Colditz G.A.}},\n\tyear = {2017},\n\tkeywords = {*antipyretic agent, *critically ill patient, Child, Cochrane Library, Embase, English (language), Medline, Scopus, adult, body temperature, controlled clinical trial, controlled study, drug therapy, economic evaluation, heart rate, hospital infection, human, hypothermia, licence, lung minute volume, medical literature, meta analysis, mortality, nervous system, nursing, observational study, odds ratio, outpatient department, randomized controlled trial, risk factor, sepsis, systematic review, volunteer}\n}\n\n","author_short":["Drewry A.M.","Ablordeppey E.A.","Murray E.T.","Stoll C.R.T.","Izadi S.R.","Dalton C.M.","Hardi A.C.","Fowler S.A.","Fuller B.M.","Colditz G.A."],"key":"drewry_a.m._antipyretic_2017","id":"drewry_a.m._antipyretic_2017","bibbaseid":"drewryam-ablordeppeyea-murrayet-stollcrt-izadisr-daltoncm-hardiac-fowlersa-etal-antipyretictherapyincriticallyillsepticpatientsasystematicreviewandmetaanalysis-2017","role":"author","urls":{"Paper":"http://journals.lww.com/ccmjournal/pages/default.aspx"},"keyword":["*antipyretic agent","*critically ill patient","Child","Cochrane Library","Embase","English (language)","Medline","Scopus","adult","body temperature","controlled clinical trial","controlled study","drug therapy","economic evaluation","heart rate","hospital infection","human","hypothermia","licence","lung minute volume","medical literature","meta analysis","mortality","nervous system","nursing","observational study","odds ratio","outpatient department","randomized controlled trial","risk factor","sepsis","systematic review","volunteer"],"downloads":0,"html":""},"search_terms":["antipyretic","therapy","critically","ill","septic","patients","systematic","review","meta","analysis","drewry a.m.","ablordeppey e.a.","murray e.t.","stoll c.r.t.","izadi s.r.","dalton c.m.","hardi a.c.","fowler s.a.","fuller b.m.","colditz g.a."],"keywords":["*antipyretic agent","*critically ill patient","child","cochrane library","embase","english (language)","medline","scopus","adult","body temperature","controlled clinical trial","controlled study","drug therapy","economic evaluation","heart rate","hospital infection","human","hypothermia","licence","lung minute volume","medical literature","meta analysis","mortality","nervous system","nursing","observational study","odds ratio","outpatient department","randomized controlled trial","risk factor","sepsis","systematic review","volunteer"],"authorIDs":[],"dataSources":["9LqPNaySNpNxYBFzj"]}